Alkermes has shown more of the data that persuaded it to throw money at its narcolepsy program. The phase 1b readout suggests Alkermes’ ALKS 2680 can hold its own against Takeda’s rival prospect ...

Alkermes (NASDAQ:ALKS) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives ...

Robert W. Baird analyst Joel Beatty has maintained their bullish stance on ALKS stock, giving a Buy rating on June 4. Joel Beatty has given ...

DUBLIN, June 3, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced new data from the full narcolepsy type 1 ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Alkermes just unveiled an announcement. Alkermes plc shareholders, during their 2024 Annual Meeting, approved key amendments to the company’s stock plan, including a substantial ...

Alkermes is positioned for outperformance in the pharmaceutical sector due to its conservative cash-heavy balance sheet and high-margin business model. The company focuses on therapies for alcohol ...

A month has gone by since the last earnings report for Alkermes (ALKS). Shares have lost about 2.7% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading ...

Over the past 15 years, on average, racial and ethnic diversity in multiple US regions has increased by 1% to 5%. JAMA study ...

Alkermes plc (Nasdaq: ALKS) today announced plans to present three posters related to ALKS 2680 at SLEEP 2024, the 38th ...

About Alkermes plc Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary ...

Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.